Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
- Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
- Drug Approvals
- Clinical Trial Calendar

Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard

Crypto
Cryptocurrency
Blockchain

Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies

Politics
US
World
White House
Elections
General News

Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard

Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health

Slide Shows

Entertainment
Top Stories
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre

Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services

Premium
Intelligent Investor
Biotech Investor NEW
Login

Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us

Business
Corp. News
- Latest Headlines
- Biotech
- Investors
- Stock Alerts
- IPOs
- M&A
Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
Corp. Calendars
Earnings Calendar
FDA Calendars
- Drug Approvals
- Clinical Trial Calendar
Ratings Changes
Economy
- US
- Europe
- Asia
- Global
- Economic Calendar
- Economic Scorecard
Crypto
- Cryptocurrency
- Blockchain
Markets
Market News
Politics
- US
- World
- White House
- Elections
- General News
Forex
Health
Health News
Slide Shows
Entertainment
Entertainment News
- Top Stories
Music News
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre
Content Licensing
Premium
More

Sanofi Sa (SNYNF)

Regeneron And Sanofi's Dupixent Gets EC Approval To Treat Children Aged 2-11 Years With CSU 4/13/2026 6:05:47 AM

Regeneron, Sanofi Secure EU Nod To Expand Dupixent Use In Young Children With CSU 4/13/2026 1:34:44 AM

Sanofi, Regeneron: EC Approves Dupixent For Pediatric Chronic Spontaneous Urticaria 4/13/2026 1:09:12 AM

Weekly Buzz: MGNX Resumes LINNET; GSK Wins China Nod; FDA Okays Waters; NBIX Snaps Up SLNO 4/10/2026 10:00:43 AM

Sanofi's Lunsekimig Shows Promise In Respiratory Diseases 4/7/2026 7:19:15 AM

Sanofi: Lunsekimig Meets Primary, Key Secondary Endpoints In Phase 2 Respiratory Studies 4/7/2026 1:26:08 AM

Sanofi’s Lunsekimig Shows Positive Phase 2 Results In Asthma And CRSwNP, While Missing Primary Endpoint In AD 4/7/2026 1:08:34 AM

Sanofi Receives EU Conditional Marketing Authorization For Rezurock In Chronic GVHD 3/31/2026 5:24:27 AM

Sanofi: European Commission Grants Conditional Marketing Authorisation For Rezurock 3/31/2026 1:28:06 AM

Sanofi: EU Approves Rezurock For Chronic Graft-versus-host Disease Treatment 3/31/2026 1:12:55 AM

Sanofi Gets EU Approval For Rezurock To Treat Chronic Graft-vs-host Disease 3/31/2026 1:12:54 AM

Biotech Stocks Facing FDA Decision In April 2026 3/30/2026 6:14:27 AM

Sanofi Reports Positive Phase 3 Results For Amlitelimab In Atopic Dermatitis 3/28/2026 12:31:54 PM

Weekly Buzz: CORT Wins FDA Nod In Cancer; MRK Acquires TERN; INSM Meets Trial Goals But VALN Misses 3/27/2026 9:42:17 AM

Sanofi: CHMP Adopts Positive Opinion Recommending Approval Of Sarclisa 3/27/2026 8:23:36 AM

Sanofi’s Sarclisa Subcutaneous On-Body Injector Formulation Recommended For EU Approval In Multiple Myeloma 3/27/2026 8:04:05 AM

Sanofi And Regeneron's Dupixent Approved In Japan For Bullous Pemphigoid 3/24/2026 7:14:07 AM

Sanofi: MHLW In Japan Approves Dupixent To Treat Moderate-to-severe Bullous Pemphigoid 3/24/2026 2:30:42 AM

Regeneron Pharma And Sanofi: Dupixent Approved In Japan To Treat Adults With Bullous Pemphigoid 3/24/2026 2:07:18 AM

Sanofi's Venglustat Gets FDA Breakthrough Therapy Designation For Type 3 Gaucher Disease 3/18/2026 8:58:40 AM

- 1
- 2
- 3
- Next »

Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us | Contact Us | Privacy | Sitemap